Revenue Breakdown
Composition ()
No data
Revenue Streams
Profitability & Margins
Evaluating the bottom line, Mainz Biomed NV maintains a gross margin of 66.12%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -2822.07%, while the net margin is -2910.26%. These profitability ratios, combined with a Return on Equity (ROE) of N/A, provide a clear picture of how effectively MYNZ converts its operational activities into shareholder value.
Comparative Benchmarking
In the context of the broader market, MYNZ competes directly with industry leaders such as PHGE and ALBT. With a market capitalization of $10.47M, it holds a leading position in the sector. When comparing efficiency, MYNZ's gross margin of 66.12% stands against PHGE's N/A and ALBT's 33.06%. Such benchmarking helps identify whether Mainz Biomed NV is trading at a premium or discount relative to its financial performance.
